Cite
HARVARD Citation
Heinrich, K. et al. (2021). Gender-dependent survival benefit from first-line irinotecan in metastatic colorectal cancer. Subgroup analysis of a phase III trial (XELAVIRI-study, AIO-KRK-0110). European journal of cancer. pp. 128-139. [Online].